Eli Lilly & Co. Bio-Medicines President Christi Shaw has been at the company for over a year now, responsible for the big pharma's commercial portfolio excluding diabetes and oncology. She stepped into the shoes previously filled by David Ricks, who moved up to lead the company as CEO, and is tasked with overseeing new drug launches in some of the industry's most competitive categories.
For example, she is overseeing the launch of the blockbuster contender Taltz (ixekizumab) for psoriasis and psoriatic arthritis, and will...






